Research never stops

Boehringer Ingelheim/Various

In 2004, Evotec entered into a multi-year, multi-target drug discovery alliance with Boehringer Ingelheim to jointly identify and develop pre-clinical development candidates for the treatment of various disease areas including CNS, inflammation, cardiometabolic and respiratory diseases. In 2009, the collaboration was extended for an additional four years and the scope expanded to include oncology targets. Under the terms of the agreement, Boehringer Ingelheim has full ownership and global responsibility for clinical development, manufacturing and commercialisation of the compounds identified. In return, Evotec received research payments and pre-clinical milestones. Furthermore, the contract provides substantial long-term upside for Evotec through potential payments for successful milestone achievements during clinical development and royalties when new drugs reach the market. Currently, there is one active Phase I clinical trial in oncology.

In June 2013, a milestone was reached for the transition of a pain molecule into pre-clinical development.

In September 2013, two milestones were reached in this alliance with Boehringer Ingelheim. The first milestone was for the transition of an oncology molecule into Phase I clinical trials. The second milestone, which is the 20th milestone as part of the alliance with Boehringer Ingelheim, recognises a second oncology compound transitioning into pre-clinical development. Another milestone in this alliance was reached in November 2013 for the transition of an oncology molecule into pre-clinical development.

In June 2014, a milestone was reached for the transition of a back-up compound from a respiratory programme into pre-clinical development.